Author of

• 36459

  +

  P78 - Immunotherapy (Phase II/III Trials) - Immune Checkpoint Inhibitor Single Agent (ID 255)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Immunotherapy (Phase II/III Trials)
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 36464

    +

    P78.04 - Efficacy and Safety Analysis of Atezolizumab Monotherapy in Patients With Non-Small Cell Lung Cancer (ID 1128)

    00:00 - 00:00  |  Presenting Author(s): Kazutoshi Komiya
    • Abstract
    • Slides

    Introduction
    

    It has been reported that atezolizumab, an anti PD-L1 antibody, has a lower frequency of drug-induced interstitial lung disease (ILD) than anti PD-1 antibody, but its safety in patients with interstitial pneumonia (IP) as the underlying disease has not been elucidated.

    Methods
    

    A total 33 patients were studied who had non-small cell lung cancer and received atezolizumab monotherapy in the 2nd line therapy and thereafter at Saga University Medical School Hospital and Ureshino Medical Center between May 2018 and September 2019. We retrospectively examined the efficacy, prognosis, and safety of atezolizumab monotherapy.

    Results
    

    There were nine patients (27.3%) with IP as the underlying disease. The therapeutic response rate was 6.1%, and the disease control rate was 45.5%. The median progression-free survival was 4.9 months (95% confidence interval, 3.0 to 7.3). Discontinuation due to immune-related adverse events occurred in nine patients (27.3%), most of which was due to drug-induced ILD (5/9, 55.6%). There were no deaths due to drug-induced ILD. The prevalence of drug-induced ILD was 16.7% (4/24) in cases without IP as the underlying disease, and it was 11.1% (1/9) with IP, but the difference was not statistically significant (p=0.69). We have been reported that drug-induced ILD was significantly higher in those with IP as the underlying disease (50.0%) than in those without (6%, p=0.001) at anti-PD-1 (nivolumab or pembrolizumab) antibody monotherapy. In patients with IP as the underlying disease, atezolizumab monotherapy tended to have a lower frequency of drug-induced ILD (11.1% vs 50.0%, p=0.06).

    Conclusion
    

    In patients with IP as the underlying disease, it was suggested that anti PD-L1 antibody monotherapy tended to have lower frequency of drug-induced ILD than anti-PD-1 antibody monotherapy.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.